https://inflectisbioscience.reportablenews.com daily 1.0 https://inflectisbioscience.reportablenews.com/pr/aix-marseille-universite-amu-and-inflectis-bioscience-expand-therapeutic-promise-of-ifb-088-to-axonal-forms-of-charcot-marie-tooth-disease 2025-09-03T13:13:03Z monthly 0.5 https://inflectisbioscience.reportablenews.com/pr/inflectis-bioscience-announces-publication-of-groundbreaking-study-on-ifb-088-s-therapeutic-potential-in-als-in-life-science-alliance 2025-09-02T12:46:20Z monthly 0.5 https://inflectisbioscience.reportablenews.com/pr/inflectis-positive-prelim-results-of-ifb-088-in-ph2-study 2025-02-06T12:00:00Z monthly 0.5 https://inflectisbioscience.reportablenews.com/pr/inflectis-bioscience-awarded-650k-grant-from-the-national-multiple-sclerosis-society-to-advance-ifb-048-preclinical-development-in-multiple-sclerosis-research-to-be-performed-by-prof-popko-of-northwestern-university 2024-04-30T10:30:00Z monthly 0.5 https://inflectisbioscience.reportablenews.com/pr/inflectis-completes-enrollment-phase-2-trial-of-ifb-088-in-als 2024-01-31T11:00:00Z monthly 0.5 https://inflectisbioscience.reportablenews.com/pr/inflectis-awarded-943k-grant-from-als-assoc 2024-01-03T20:00:00Z monthly 0.5 https://inflectisbioscience.reportablenews.com/pr/inflectis-bioscience-doses-first-patient-with-ifb-088-in-a-phase-2-clinical-trial-for-the-treatment-of-amyotrophic-lateral-sclerosis 2022-12-19T08:00:00Z monthly 0.5 https://inflectisbioscience.reportablenews.com/pr/inflectis-granted-odd-for-ifb-088 2022-03-28T03:00:00Z monthly 0.5 https://inflectisbioscience.reportablenews.com/pr/inflectis-receives-approval-to-initiate-als-trial-in-france 2022-01-10T07:00:00Z monthly 0.5 https://inflectisbioscience.reportablenews.com/pr/inflectis-expands-leadership 2021-10-04T08:25:00Z monthly 0.5 https://inflectisbioscience.reportablenews.com/pr/inflectis-bioscience-licenses-rights-to-a-potential-new-class-of-therapies-for-demyelinating-diseases-from-the-university-of-chicago 2021-06-22T07:00:00Z monthly 0.5 https://inflectisbioscience.reportablenews.com/pr/clinical-study-demonstrates-promising-results-for-als 2021-04-29T10:40:51Z monthly 0.5 https://inflectisbioscience.reportablenews.com/pr/inflectis-bioscience-announces-successful-completion-of-phase-1-clinical-trial-of-oral-ifb-088 2020-01-07T08:00:00Z monthly 0.5 https://inflectisbioscience.reportablenews.com/pr/inflectis-bioscience-announces-favorable-results-for-ifb-088-phase-1-single-ascending-dose-clinical-trial 2019-05-15T08:00:00Z monthly 0.5 https://inflectisbioscience.reportablenews.com/pr/inflectis-bioscience-ifb-088-enters-phase-1-clinical-trial 2018-05-22T08:00:00Z monthly 0.5